Invuity, Inc., a medical technology company, develops various surgical devices to address various surgical procedures in the United States. The company integrates its intelligent photonics technology platform into its single-use and reusable advanced surgical devices to address various critical intracavity illumination and visualization challenges. It offers various illuminated surgical devices, including Eikon LT Illuminated and Eikon illuminated retractor systems for breast oncology/oncoplastic/general/orthopedics surgeries; Saber Yankauer, a handheld illuminator for orthopedic/spine/cardiothoracic/breast/general surgeries; and Saber Frazier, a handheld illuminator for spine/orthopedic/neurosurgery surgeries. The company also provides Eika illuminated retractor systems for anterior neck approaches comprising thyroid and cervical spine surgeries; Breiten illuminated retractor systems for spine surgeries; Eipex illuminated retractor systems for spine/orthopedic surgeries; Eivector illuminated and Eiberg Illuminated retractor systems for orthopedic surgeries; and Waveguide XT system, a drop-in intracavity illuminator for spine surgeries. Invuity, Inc. sells its devices through its direct sales representatives and independent sales agents; and directly to hospitals and surgeons, as well as to third-party medical device manufacturers. The company was formerly known as Spotlight Surgical, Inc. and changed its name to Invuity, Inc. in 2007. Invuity, Inc. was incorporated in 2004 and is based in San Francisco, California.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Instruments & Supplies
- Sub-Industry: N/A
- Symbol: NASDAQ:IVTY
- CUSIP: N/A
- Web: www.invuity.com
- Market Cap: $141.52 million
- Outstanding Shares: 17,050,000
- 50 Day Moving Avg: $8.40
- 200 Day Moving Avg: $8.40
- 52 Week Range: $4.50 - $14.00
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.91
- P/E Growth: -0.14
- Annual Revenue: $36.63 million
- Price / Sales: 3.86
- Book Value: $0.75 per share
- Price / Book: 11.07
- EBIDTA: ($35,610,000.00)
- Net Margins: -114.61%
- Return on Equity: -140.69%
- Return on Assets: -68.16%
- Debt-to-Equity Ratio: 1.51%
- Current Ratio: 3.07%
- Quick Ratio: 2.63%
- Average Volume: 93,971 shs.
- Beta: -0.19
- Short Ratio: 6.06
Frequently Asked Questions for Invuity (NASDAQ:IVTY)
What is Invuity's stock symbol?
Invuity trades on the NASDAQ under the ticker symbol "IVTY."
How were Invuity's earnings last quarter?
Invuity, Inc. (NASDAQ:IVTY) announced its earnings results on Tuesday, July, 25th. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.54) by $0.07. The business earned $9.77 million during the quarter, compared to analyst estimates of $10.30 million. Invuity had a negative return on equity of 140.69% and a negative net margin of 114.61%. View Invuity's Earnings History.
When will Invuity make its next earnings announcement?
Where is Invuity's stock going? Where will Invuity's stock price be in 2017?
4 brokerages have issued 12 month target prices for Invuity's shares. Their predictions range from $10.00 to $13.00. On average, they anticipate Invuity's share price to reach $11.00 in the next twelve months. View Analyst Ratings for Invuity.
What are analysts saying about Invuity stock?
Here are some recent quotes from research analysts about Invuity stock:
- 1. According to Zacks Investment Research, "Invuity, Inc. is a medical technology company. Its products include Eikon Illuminated Retractor System, Saber Yankauer, Saber Frazier, Eika Illuminated Retractor System, Breiten Illuminated Retractor System, Eipex Illuminated Retractor System, Eivector Illuminated Retractor System and Waveguide XT System. The Company sells its devices through its direct sales representatives and original equipment manufacturers of surgical systems. Invuity, Inc. is based in San Francisco, California. " (7/28/2017)
- 2. Stifel Nicolaus analysts commented, "Following Invuity's early January top-line pre-announcement giving a potential $9.1M-$9.3M revenue range, the company's full 4Q16 release and call provided both more positive details on the quarter and critical revenue measures, all of which suggests the business has stabilized after slower than expected 3Q16 results. At $9.4M, 4Q16 sales were a touch ahead of the company's preliminary range. Encouragingly, revenue per account at $12,100 (+10% Y/Y, 5% Q/Q) -- a critical measure for assessing the company's "go-deep" strategy -- appears stable. Equally impressive, the company continued to expand its active hospital account base which now stands at 745 (+41% Y/Y). Management again reaffirmed 2017 top-line guidance of $42M-$44M, which, in our view, could prove conservative given 4Q16 stable revenue/account, new accounts adds, and "modest" contribution from the mid-year 2017 expected full launch of PhotonBlade. We continue to believe Invuity's highly differentiated, and expanding, portfolio of procedure enhancing technologies will continue to demonstrate meaningful growth potential across a broad array of medical specialties. At current valuation levels, 1.6x 2018 EV/R (peer group: ~3.0x), Invuity would appear undervalued, given the company's significant top-line growth outlook. We rate Invuity shares Buy with a now higher $9 (from $8) target price." (2/15/2017)
Are investors shorting Invuity?
Invuity saw a increase in short interest in August. As of August 15th, there was short interest totalling 1,011,546 shares, an increase of 49.3% from the July 31st total of 677,615 shares. Based on an average daily trading volume, of 200,883 shares, the days-to-cover ratio is currently 5.0 days. Approximately 8.5% of the company's shares are short sold.
Who are some of Invuity's key competitors?
Some companies that are related to Invuity include Athersys (ATHX), Utah Medical Products (UTMD), RTI Surgical (RTIX), Aratana Therapeutics (PETX), Strongbridge Biopharma PLC (SBBP), Immune Design Corp. (IMDZ), Arrowhead Pharmaceuticals (ARWR), Curis (CRIS), Forward Pharma A/S (FWP), Stemline Therapeutics (STML), Ardelyx (ARDX), Syndax Pharmaceuticals (SNDX), Enzymotec (ENZY), Neos Therapeutics (NEOS), DURECT Corporation (DRRX), Mirati Therapeutics (MRTX), uniQure N.V. (QURE) and Kura Oncology (KURA).
When did Invuity IPO?
(IVTY) raised $48 million in an initial public offering on the week of June 15th 2015. The company issued 4,000,000 shares at $12.00 per share. Piper Jaffray, Leerink Partners and Stifel acted as the underwriters for the IPO and William Blair was co-manager.
Who owns Invuity stock?
Invuity's stock is owned by a number of of retail and institutional investors. Top institutional investors include
DISCOVERY GROUP I, LLC
(7.10%), InterWest Venture Management Co (6.36%), FMR LLC (4.80%), Lyon Street Capital LLC (4.48%), B. Riley Financial Inc. (2.93%) and Cowen Prime Services LLC (2.76%). Company insiders that own Invuity stock include Alex Vayser, Eric W Roberts, Gregory T Lucier, James E Flynn, James H Mackaness, Philip M Sawyer, Reza Zadno and Robert Gerberich. View Institutional Ownership Trends for Invuity.
Who sold Invuity stock? Who is selling Invuity stock?
Invuity's stock was sold by a variety of institutional investors in the last quarter, including Granite Investment Partners LLC and FMR LLC. Company insiders that have sold Invuity stock in the last year include Alex Vayser, Eric W Roberts, James E Flynn, Philip M Sawyer, Reza Zadno and Robert Gerberich. View Insider Buying and Selling for Invuity.
Who bought Invuity stock? Who is buying Invuity stock?
Invuity's stock was purchased by a variety of institutional investors in the last quarter, including B. Riley Financial Inc., Summit Partners Public Asset Management LLC, Cowen Prime Services LLC, Royce & Associates LP, Vanguard Group Inc., OxFORD Asset Management LLP, Lyon Street Capital LLC and CAPROCK Group Inc.. Company insiders that have bought Invuity stock in the last two years include Eric W Roberts, Gregory T Lucier and James H Mackaness. View Insider Buying and Selling for Invuity.
How do I buy Invuity stock?
Shares of Invuity can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Invuity's stock price today?
MarketBeat Community Rating for Invuity (NASDAQ IVTY)MarketBeat's community ratings are surveys of what our community members think about Invuity and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Invuity stock can currently be purchased for approximately $8.30.
Earnings History for Invuity (NASDAQ:IVTY)Earnings History by Quarter for Invuity (NASDAQ IVTY)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|7/25/2017||Q2 2017||($0.54)||($0.61)||$10.30 million||$9.77 million||View||N/A|
|4/26/2017||Q1 2017||($0.61)||($0.64)||$8.71 million||$9.02 million||View||N/A|
|2/14/2017||Q4 2016||($0.56)||($0.56)||$9.14 million||$9.36 million||View||Listen|
|11/3/2016||Q3||($0.62)||($0.56)||$9.29 million||$8.48 million||View||Listen|
|7/19/2016||Q2||($0.81)||($0.76)||$8.04 million||$8.20 million||View||Listen|
|5/5/2016||Q1||($0.68)||($0.90)||$6.10 million||$6.40 million||View||Listen|
|2/24/2016||Q4||($0.72)||($0.76)||$5.77 million||$6.25 million||View||Listen|
|11/10/2015||Q315||($0.96)||($0.69)||$5.05 million||$5.60 million||View||Listen|
|8/11/2015||Q215||($0.75)||($3.20)||$4.55 million||$4.70 million||View||Listen|
Earnings Estimates for Invuity (NASDAQ:IVTY)
2017 EPS Consensus Estimate: ($1.85)
2018 EPS Consensus Estimate: ($1.26)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Invuity (NASDAQ:IVTY)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Invuity (NASDAQ:IVTY)
Insider Ownership Percentage: 10.50%Insider Trades by Quarter for Invuity (NASDAQ:IVTY)
Institutional Ownership Percentage: 68.87%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/18/2017||Eric W Roberts||Director||Buy||6,500||$7.07||$45,955.00|| |
|5/15/2017||Eric W Roberts||Director||Buy||5,000||$7.88||$39,400.00|| |
|5/9/2017||Eric W Roberts||Director||Buy||2,000||$8.80||$17,600.00|| |
|5/3/2017||Reza Zadno||Director||Sell||4,000||$9.16||$36,640.00|| |
|12/14/2016||James E Flynn||Insider||Sell||184,796||$6.22||$1,149,431.12|| |
|11/8/2016||James H Mackaness||CFO||Buy||1,700||$5.75||$9,775.00|| |
|10/17/2016||Eric W Roberts||Director||Sell||1,000||$12.08||$12,080.00|| |
|10/6/2016||Philip M Sawyer||Insider||Sell||900||$13.01||$11,709.00|| |
|10/6/2016||Robert Gerberich||VP||Sell||1,500||$12.72||$19,080.00|| |
|10/3/2016||Alex Vayser||Insider||Sell||3,000||$13.18||$39,540.00|| |
|9/22/2016||Eric W Roberts||Director||Sell||2,201||$14.00||$30,814.00|| |
|9/15/2016||Eric W Roberts||Director||Sell||5,000||$13.47||$67,350.00|| |
|9/2/2016||Eric W Roberts||Director||Sell||26,839||$14.00||$375,746.00|| |
|9/1/2016||Alex Vayser||Insider||Sell||7,000||$14.00||$98,000.00|| |
|8/24/2016||Alex Vayser||Insider||Sell||9,000||$12.78||$115,020.00|| |
|8/24/2016||Robert Gerberich||VP||Sell||10,500||$12.53||$131,565.00|| |
|8/23/2016||Eric W Roberts||Director||Sell||5,000||$12.00||$60,000.00|| |
|7/21/2016||Alex Vayser||Insider||Sell||12,000||$12.00||$144,000.00|| |
|7/21/2016||Eric W Roberts||Director||Sell||42,000||$12.00||$504,000.00|| |
|6/10/2016||Gregory T Lucier||Director||Buy||8,442||$7.56||$63,821.52|| |
|6/7/2016||Gregory T Lucier||Director||Buy||5,601||$7.00||$39,207.00|| |
|6/6/2016||Gregory T Lucier||Director||Buy||26,728||$6.90||$184,423.20|| |
|5/18/2016||James H Mackaness||CFO||Buy||2,000||$5.08||$10,160.00|| |
Headline Trends for Invuity (NASDAQ:IVTY)
Latest Headlines for Invuity (NASDAQ:IVTY)
|Ekso Bionics Holdings (EKSO) & Invuity (IVTY) Critical Contrast|
www.americanbankingnews.com - September 18 at 2:30 PM
|Invuity to Present at Cantor Fitzgerald Global Healthcare Conference|
finance.yahoo.com - September 14 at 6:39 AM
|Zacks: Brokerages Anticipate Invuity, Inc. (IVTY) Will Post Quarterly Sales of $10.15 Million|
www.americanbankingnews.com - September 11 at 11:36 AM
|Invuity (IVTY) and Ekso Bionics Holdings (EKSO) Head-To-Head Analysis|
www.americanbankingnews.com - September 11 at 10:40 AM
|Invuity (IVTY) and Ekso Bionics Holdings (EKSO) Financial Review|
www.americanbankingnews.com - September 5 at 10:22 AM
|Invuity, Inc. (IVTY) Rating Increased to Sell at ValuEngine|
www.americanbankingnews.com - September 3 at 12:28 AM
|Invuity, Inc. (IVTY) Receives Average Rating of "Hold" from Brokerages|
www.americanbankingnews.com - September 2 at 10:40 AM
|Invuity, Inc. (IVTY) Appoints Daniel Wolterman to Board|
www.streetinsider.com - September 1 at 1:09 AM
|Daniel Wolterman Joins Invuity’s Board of Directors|
finance.yahoo.com - August 31 at 6:25 AM
|Ekso Bionics Holdings (EKSO) vs. Invuity (IVTY) Head-To-Head Comparison|
www.americanbankingnews.com - August 28 at 8:10 PM
|Invuity, Inc. (IVTY) Sees Significant Increase in Short Interest|
www.americanbankingnews.com - August 28 at 1:20 AM
|$10.15 Million in Sales Expected for Invuity, Inc. (IVTY) This Quarter|
www.americanbankingnews.com - August 23 at 11:06 AM
|ETFs with exposure to Invuity, Inc. : August 8, 2017|
finance.yahoo.com - August 8 at 7:43 PM
|Invuity, Inc. (IVTY) Receives Consensus Recommendation of "Buy" from Analysts|
www.americanbankingnews.com - August 8 at 11:04 AM
|Zacks: Analysts Expect Invuity, Inc. (NASDAQ:IVTY) Will Announce Quarterly Sales of $10.15 Million|
www.americanbankingnews.com - August 5 at 7:42 AM
|Zacks: Analysts Anticipate Invuity, Inc. (NASDAQ:IVTY) Will Post Earnings of -$0.56 Per Share|
www.americanbankingnews.com - August 3 at 8:24 AM
|Head to Head Comparison: Invuity (NASDAQ:IVTY) and Strata Skin Sciences (SSKN)|
www.americanbankingnews.com - July 30 at 7:27 AM
|Zacks Investment Research Downgrades Invuity, Inc. (NASDAQ:IVTY) to Sell|
www.americanbankingnews.com - July 29 at 12:58 AM
|William Blair Equities Analysts Reduce Earnings Estimates for Invuity, Inc. (NASDAQ:IVTY)|
www.americanbankingnews.com - July 28 at 12:39 PM
|Leerink Swann Weighs in on Invuity, Inc.'s Q3 2017 Earnings (NASDAQ:IVTY)|
www.americanbankingnews.com - July 28 at 11:27 AM
|Financial Comparison: Invuity (NASDAQ:IVTY) vs. Strata Skin Sciences (SSKN)|
www.americanbankingnews.com - July 28 at 8:10 AM
|Invuity, Inc. :IVTY-US: Earnings Analysis: Q2, 2017 By the Numbers : July 27, 2017|
finance.yahoo.com - July 27 at 11:29 PM
|Edited Transcript of IVTY earnings conference call or presentation 25-Jul-17 9:00pm GMT|
finance.yahoo.com - July 27 at 5:19 AM
|Invuity, Inc. (NASDAQ:IVTY) Announces Quarterly Earnings Results, Misses Estimates By $0.07 EPS|
www.americanbankingnews.com - July 26 at 1:06 PM
|Investor Network: Invuity Inc to Host Earnings Call|
finance.yahoo.com - July 25 at 8:53 PM
|Invuity Reports 2017 Second Quarter, Six-Month Financial Results|
finance.yahoo.com - July 25 at 8:53 PM
|Invuity reports 2Q loss|
finance.yahoo.com - July 25 at 8:53 PM
|Financial Comparison: Unilife Corp (UNIS) & Invuity (NASDAQ:IVTY)|
www.americanbankingnews.com - July 21 at 10:16 AM
|Invuity, Inc. (NASDAQ:IVTY) Expected to Announce Quarterly Sales of $10.30 Million|
www.americanbankingnews.com - July 14 at 4:21 PM
|Strata Skin Sciences (SSKN) vs. Invuity (NASDAQ:IVTY) Head-To-Head Contrast|
www.americanbankingnews.com - July 14 at 12:57 PM
|Invuity, Inc. (NASDAQ:IVTY) Given Consensus Rating of "Buy" by Analysts|
www.americanbankingnews.com - July 14 at 11:18 AM
|Invuity Inc. Showcased PhotonBlade at Premier Inc.’s Annual Breakthroughs Conference|
finance.yahoo.com - July 13 at 3:48 AM
|Invuity, Inc. (IVTY) Expected to Post Earnings of -$0.54 Per Share|
www.americanbankingnews.com - July 12 at 8:18 AM
|Invuity Announces 2017 Second Quarter Financial Results and Conference Call Date|
finance.yahoo.com - July 12 at 12:13 AM
|Financial Survey: Invuity (NASDAQ:IVTY) and Unilife Corp (UNIS)|
www.americanbankingnews.com - July 3 at 9:00 AM
|Head to Head Survey: Strata Skin Sciences (SSKN) & Invuity (NASDAQ:IVTY)|
www.americanbankingnews.com - July 1 at 2:22 PM
|Invuity, Inc. (IVTY) Rating Increased to Hold at Zacks Investment Research|
www.americanbankingnews.com - June 28 at 12:38 AM
|Invuity, Inc. (IVTY) Given Average Rating of "Buy" by Analysts|
www.americanbankingnews.com - June 19 at 11:04 AM
|Northland Securities Reiterates "$13.00" Price Target for Invuity, Inc. (IVTY)|
www.americanbankingnews.com - June 18 at 3:02 PM
|Invuity, Inc. (IVTY) Expected to Announce Quarterly Sales of $10.30 Million|
www.americanbankingnews.com - June 18 at 10:48 AM
|Zacks: Analysts Expect Invuity, Inc. (IVTY) Will Announce Earnings of -$0.55 Per Share|
www.americanbankingnews.com - June 16 at 11:38 AM
|Invuity, Inc. (IVTY) Rating Lowered to Sell at Zacks Investment Research|
www.americanbankingnews.com - June 13 at 12:52 PM
|Invuity Provides Update on PhotonBlade Commercialization|
finance.yahoo.com - June 13 at 10:49 AM
|Invuity, Inc. (IVTY) Short Interest Update|
www.americanbankingnews.com - June 10 at 7:22 AM
|ETFs with exposure to Invuity, Inc. : June 8, 2017|
finance.yahoo.com - June 8 at 6:59 PM
|Halyard Health (HYH) vs. Invuity (IVTY) Head-To-Head Review|
www.americanbankingnews.com - June 6 at 6:22 PM
|Invuity to Present at William Blair Growth Stock Conference|
finance.yahoo.com - May 30 at 5:48 PM
|Zacks Investment Research Upgrades Invuity, Inc. (IVTY) to Hold|
www.americanbankingnews.com - May 27 at 12:20 AM
|Invuity, Inc. (IVTY) to Post Q2 2017 Earnings of ($0.51) Per Share, William Blair Forecasts|
www.americanbankingnews.com - May 25 at 7:22 AM
|Invuity, Inc. (IVTY) Research Coverage Started at William Blair|
www.americanbankingnews.com - May 23 at 10:37 PM
Invuity (IVTY) Chart for Saturday, September, 23, 2017